Ranbaxy facilities in India under review: Health Minister

Subscribe to GoodReturns

Ranbaxy facilities in India under review: Health Minister
Health Minister Gulam Nabi Azad has said that Ranbaxy facilities in India are being reviewed after its US arm admitted to manufacturing certain drugs not in conformity with good manufacturing practices and which are considered "adulterated" under US law.

However, in India manufacturing of drugs not in conformity with GMP is viewed as non-compliance to GMP under the said Act & Rules, he said.

The Drugs Controller General of India has been ordered to review facilities of Ranbaxy in the country to ascertain the quality of drugs manufactured for domestic market, he said.

Earlier, Ranbaxy agreed to pay the fine of USD 500 million after its US arm pleaded guilty.

Dion Global Solutions Ltd.

Read more about: ranbaxy laboratories
Story first published: Wednesday, August 7, 2013, 9:20 [IST]
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

Thousands of Goodreturn readers receive our evening newsletter.
Have you subscribed?